Citi Pharma Limited has approved the initial public offering (IPO) of its wholly owned subsidiary, Citi Veterinary Pharma Limited, with plans to raise between Rs. 1.0 billion and Rs. 2.0 billion.
In a material information notice submitted to the Pakistan Stock Exchange on March 3, 2026, the company stated that its Board of Directors has formally approved the initiation of the IPO process.
The Board has also appointed K Trade Securities Limited as Consultant to Issue, with the objective of listing the subsidiary at the earliest opportunity.
Citi Veterinary Pharma Limited has been established as a dedicated entity focused on the manufacturing of veterinary APIs and pharmaceutical products for the local market. The move marks a strategic step by Citi Pharma to diversify its revenue base within the broader pharmaceutical sector.
The company further disclosed that it expects to generate approximately Rs. 1.50 billion in revenue from trading of veterinary products in FY26, signaling growth ambitions in the animal health segment.
Get the latest business news, market insights, and economic updates wherever you prefer.
Add ProPakistani to Preferred Sources and see more of our stories in Google Search and Top Stories.